Photo of Alexey V. Danilov, M.D., Ph.D.

Alexey V. Danilov M.D., Ph.D.

    • Associate Professor of Medicine School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Dr. Alexey Danilov is a physician with special expertise in lymphoma and chronic lymphocytic leukemia. In addition to taking care of patients with lymphoma and CLL, Dr. Danilov initiates and leads clinical trials and heads a research laboratory which investigates novel therapeutic targets in lymphoma. Importantly, in collaboration with industry, his research team translates bench discoveries into early-phase clinical trials, which are poised to improve lives of patients by developing safe and effective new treatments. Dr. Danilov is a Lymphoma Research Foundation Clinical Investigator and a Knight Research Scholar. He and his research team are recipients of numerous awards, including the Leukemia and Lymphoma Society Translational Research Program Award, American Society of Hematology Abstract Achievement Award, Gazzaniga Family Prize, Professor Albitski Prize and others. His research is consistently featured at national and international meetings.

Dr. Danilov developed new clinical trials which target the tumor-supporting niche; optimized treatment regimens for older patients with CLL; defined novel ways to target the tumor niche in lymphoma and CLL; discovered how novel class of drugs, CDK inhibitors, kill tumor cells.

Read more


  • M.D., Yaroslavl State Medical Academy, Yaroslavl 1997
  • Ph.D., Yaroslavl State Medical Academy, Yaroslavl 2000
  • Residency:

    • Internal medicine, Brown University School of Medicine, 2007
  • Fellowship:

    • Hematology-oncology, Tufts Medical Center, Boston, 2010
  • Certifications:

    • American Board of Internal Medicine: internal medicine, 2007
    • American Board of Internal Medicine: medical oncology, 2010
    • American Board of Internal Medicine: hematology, 2012


  • "Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib." Cancer In: , Vol. 124, No. 15, 01.08.2018, p. 3192-3200.
  • "Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy." Cancer In: , Vol. 124, No. 11, 01.06.2018, p. 2306-2315.
  • "Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples." Oncotarget In: , Vol. 9, No. 37, 15.05.2018, p. 24576-24589.
  • "Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma." Leukemia and Lymphoma In: , 18.04.2018, p. 1-9.
  • "Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia." Leukemia and Lymphoma  In: , 19.12.2017, p. 1-3.
  • "SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia." Haematologica In: , Vol. 102, No. 11, 27.10.2017, p. 1890-1900.
  • "Role for ZAP-70 signaling in the differential effector functions of rituximab and obinutuzumab (GA101) in chronic lymphocytic leukemia B cells." Journal of Immunology In: , Vol. 199, No. 4, 15.08.2017, p. 1275-1282.
  • "Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities–is there an optimal dose?" Expert Review of Hematology In: , Vol. 10, No. 8, 03.08.2017, p. 707-718.
  • "Ibrutinib-associated bleeding : pathogenesis, management and risk reduction strategies." Journal of Thrombosis and Haemostasis In: , Vol. 15, No. 5, 01.05.2017, p. 835-847.
  • "Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma." British Journal of Clinical Pharmacology In: , Vol. 83, No. 4, 2017, p. 846-854.
  • "Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis." Oncotarget In: , Vol. 8, No. 13, 2017, p. 21128-21139.
  • "Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2." Molecular Cancer Therapeutics  In: , Vol. 15, No. 11, 01.11.2016, p. 2758-2766.
  • "Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL) : a sub-analysis of SWOG S0816 Phase 2 trial." Leukemia and Lymphoma In: , 07.07.2016, p. 1-5.
  • "Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105." Cancer Biology and Therapy  In: , 11.02.2016, p. 1-9.
  • "Cardiac non-Hodgkin's lymphoma : Clinical characteristics and trends in survival." European Journal of Haematology In: , 2016.
  • "A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities." British Journal of Haematology In: , 2016.
  • "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia." British Journal of Haematology In: , 2016.
  • "Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy." Cutis In: , Vol. 98, No. 4, 2016, p. E13-E15.
  • "Urticarial linear IgA bullous dermatosis (LABD) as a presenting sign of chronic lymphocytic leukemia (CLL)." JAAD Case Reports  In: , Vol. 1, No. 6, 01.11.2015, p. 412-414.
  • "Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells." PLoS One In: , Vol. 10, No. 11, e0143685, 01.11.2015.
  • "Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange." Journal of Clinical Apheresis In: , Vol. 30, No. 5, 01.10.2015, p. 308-310.
  • "Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia." British Journal of Haematology In: , Vol. 170, No. 5, 01.09.2015, p. 734-736.
  • "Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo." British Journal of Clinical Pharmacology In: , Vol. 80, No. 3, 01.09.2015, p. 493-501.
  • "Pericardial involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma." Blood In: , Vol. 126, No. 3, 16.07.2015, p. 424.
  • "MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia." British Journal of Haematology In: , Vol. 170, No. 2, 01.07.2015, p. 272-275.
  • "Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia b cells to Alkylating agents." Cell Death and Disease In: , Vol. 6, No. 7, e1807, 01.07.2015.
  • "CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110." Cancer Research  In: , Vol. 75, No. 10, 15.05.2015, p. 2029-2038.
  • "Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells." Leukemia and Lymphoma In: , Vol. 56, No. 5, 01.05.2015, p. 1566-1569.
  • "Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia - response to Rider et al." British Journal of Haematology In: , 2015.
  • "A new hope : Novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53." British Journal of Haematology In: , Vol. 167, No. 2, 01.10.2014, p. 149-161.

Additional information

Edit profile